Loss of AT-Rich Interactive Doman 1A Expression in Gastrointestinal Malignancies
Loss of AT-Rich Interactive Doman 1A Expression in Gastrointestinal Malignancies
复制标题
DOI：
10.1159/000369140
复制
发表时间：
2015-01-01
期刊：
影响因子：
3.5
通讯作者：
Kang, Sung-Bum
中科院分区：
文献类型：
--
作者：
Lee, Soo Young;Kim, Duck-Woo;Kang, Sung-Bum
目的：富含AT的相互作用结构域1 A(ARID1 A)是近年来发现的一种新的肿瘤抑制因子，存在于多种肿瘤类型中。本研究旨在探讨ARID1A在结直肠癌(CRC)和胃癌(GC)中表达缺失的临床意义和对预后的影响。方法：应用包含196例大肠癌和275例胃癌的组织芯片以及配对的正常粘膜进行ARID1A的免疫组织化学研究。结果：我们发现6.1%(12/196)的结直肠癌和8.0%(22/275)的胃癌ARID1A表达缺失。在所有患者中，ARID1A在配对的粘膜上皮细胞中表达正常。在结直肠癌中，ARID1a的表达缺失与阴性淋巴侵袭(p=0.003)、较大的肿瘤体积(p=0.037)以及两种类型的结直肠癌(p=0.010；p=0.031)的肿瘤边界扩大显著相关。结论：ARID1A表达缺失在结直肠癌和胃癌中并不常见，与肿瘤预后无关，但可能与侵袭性较小的临床病理特征有关。需要对更多的受试者进行进一步的研究，以确定ARID1A表达缺失可能的预后影响。(C)2014年S.Karger AG，巴塞尔
Objective: AT-rich interactive domain 1A (ARID1A) has recently been identified as a novel tumor suppressor in various tumor types. This study was designed to explore the clinical relevance and prognostic impact of ARID1A expression loss in colorectal cancer (CRC) and gastric cancer (GC).Methods: Immunohistochemistry for ARID1 A was performed using tissue microarray blocks containing 196 CRCs and 275 GCs, along with paired normal mucosa. Data on clinicopathologic variables and oncologic outcomes of patients were collected and analyzed.Results: We identified 6.1% (12/196) CRC and 8.0% (22/275) GC cases showing loss of ARID1A expression. Expression of ARID1A in paired mucosal epithelial cells was normal in all patients. Loss of ARID1A expression was significantly correlated with negative lymphatic invasion (p = 0.003) in CRC, with large tumor size (p = 0.037) in GC, and with expanding tumor border in both tumor types (CRC, p = 0.010; GC, p = 0.031). However, no association was evident between ARID1A expression and 5-year overall survival in both tumor types.Conclusions: Loss of ARID1A expression is uncommon and not associated with oncologic outcome but may be related to less invasive clinicopathologic features in CRC and GC. Further studies with a larger number of subjects are needed to establish the possible prognostic impact of ARID1A expression loss.(C) 2014 S. Karger AG, Basel